Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Novel immune therapeutics for adjuvant treatment of kidney cancer

Hyung Kim, MD, Cedars-Sinai Medical Center, Los Angeles, CA, talks about a new trial investigating a drug targeting HIF-2α, in combination with pembrolizumab, as an adjuvant therapy for patients with kidney cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.